Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.12.564
K. Jones
{"title":"Pathology in Atopic Dermatitis: How it Affects Skin?","authors":"K. Jones","doi":"10.35248/2155-9554.21.12.564","DOIUrl":"https://doi.org/10.35248/2155-9554.21.12.564","url":null,"abstract":"","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"97 9 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87706717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.S8.550
M. Kawamura, Madoka Inoue, K. Matsuyama, Y. Mizutani, E. Shu, T. Miyazaki, M. Seishima
Background: Acquired reactive perforating collagenosis (ARPC) is a skin disease characterized by multiple itchy nodules, which is notably similar to the skin eruptions of prurigo nodularis (PN). The aim of this study was to prove the clinicopathological differences between ARPC and PN. Methods: We examined 22 patients with ARPC (6 males and 16 females) and 38 patients with PN (27 males and 11 females), diagnosed clinically and histologically. Transepidermal elimination of collagen which is characteristic histological findings for ARPC was found in all ARPC patients, but not in PN patients even in a serial section. Clinical findings, laboratory data, histological findings, immunohistochemical results, and efficacy of the therapies were compared between the two groups. Results: On evaluation of laboratory data, thymus and activation-regulated chemokine (TARC) levels and peripheral eosinophil counts were lower in ARPC than in PN. Histologically, we observed greater infiltration of neutrophils, histiocytes, and lymphocytes and more extensive capillaries in ARPC than in PN. Upon immunohistochemical analysis, CD163+ macrophages were found to be more abundant in the upper-to-deep dermis of ARPC, and both CD4+ T cells and CD8+ T cells were significantly increased in the mid-to-deep dermis of ARPC. The efficacies of topical steroid and antihistamines were improved by the addition of emollients in ARPC. Conclusion: This is the first report to show the histological differences in cell infiltration between the lesions of ARPC and PN. It is likely that inflammation mediated by neutrophils and M2 macrophages may be involved in the formation of ARPC lesions, as against PN lesions mediated by epidermal changes such as spongiosis. It is suggested that the addition of emollients can increase the efficacy of treatments for ARPC. However, further studies are necessary to define the precise pathomechanisms of ARPC and the effects of emollients on ARPC.
{"title":"Clinicopathological Differences between Acquired Reactive Perforating Collagenosis and Prurigo Nodularis","authors":"M. Kawamura, Madoka Inoue, K. Matsuyama, Y. Mizutani, E. Shu, T. Miyazaki, M. Seishima","doi":"10.35248/2155-9554.21.S8.550","DOIUrl":"https://doi.org/10.35248/2155-9554.21.S8.550","url":null,"abstract":"Background: Acquired reactive perforating collagenosis (ARPC) is a skin disease characterized by multiple itchy nodules, which is notably similar to the skin eruptions of prurigo nodularis (PN). The aim of this study was to prove the clinicopathological differences between ARPC and PN. Methods: We examined 22 patients with ARPC (6 males and 16 females) and 38 patients with PN (27 males and 11 females), diagnosed clinically and histologically. Transepidermal elimination of collagen which is characteristic histological findings for ARPC was found in all ARPC patients, but not in PN patients even in a serial section. Clinical findings, laboratory data, histological findings, immunohistochemical results, and efficacy of the therapies were compared between the two groups. Results: On evaluation of laboratory data, thymus and activation-regulated chemokine (TARC) levels and peripheral eosinophil counts were lower in ARPC than in PN. Histologically, we observed greater infiltration of neutrophils, histiocytes, and lymphocytes and more extensive capillaries in ARPC than in PN. Upon immunohistochemical analysis, CD163+ macrophages were found to be more abundant in the upper-to-deep dermis of ARPC, and both CD4+ T cells and CD8+ T cells were significantly increased in the mid-to-deep dermis of ARPC. The efficacies of topical steroid and antihistamines were improved by the addition of emollients in ARPC. Conclusion: This is the first report to show the histological differences in cell infiltration between the lesions of ARPC and PN. It is likely that inflammation mediated by neutrophils and M2 macrophages may be involved in the formation of ARPC lesions, as against PN lesions mediated by epidermal changes such as spongiosis. It is suggested that the addition of emollients can increase the efficacy of treatments for ARPC. However, further studies are necessary to define the precise pathomechanisms of ARPC and the effects of emollients on ARPC.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"41 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88029867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.12.565
Leroy Olaechea Varona
Nodular Melanoma (NM) is the most aggressive form of melanoma. It tends to grow more rapidly in thickness(vertically penetrate the skin) than in diameter compared to other melanoma subtypes. Instead of arising from a pre-existing mole, it may appear in a spot where a lesion did not previously exist. Since NM tends to grow in depth morequickly than it does in width, and can occur in a place that did not have a previous lesion, the prognosis is oftenworse because it takes longer for a person to be aware of the changes.
{"title":"Nodular Melanoma what are the Threats and how to Treat this Disease","authors":"Leroy Olaechea Varona","doi":"10.35248/2155-9554.21.12.565","DOIUrl":"https://doi.org/10.35248/2155-9554.21.12.565","url":null,"abstract":"Nodular Melanoma (NM) is the most aggressive form of melanoma. It tends to grow more rapidly in thickness(vertically penetrate the skin) than in diameter compared to other melanoma subtypes. Instead of arising from a pre-existing mole, it may appear in a spot where a lesion did not previously exist. Since NM tends to grow in depth morequickly than it does in width, and can occur in a place that did not have a previous lesion, the prognosis is oftenworse because it takes longer for a person to be aware of the changes.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"244 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77481915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.S10.E119
P. R. Cunha
{"title":"Efficiency of Telemedicine in Atopic Dermatitis","authors":"P. R. Cunha","doi":"10.35248/2155-9554.21.S10.E119","DOIUrl":"https://doi.org/10.35248/2155-9554.21.S10.E119","url":null,"abstract":"","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"72 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82456351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.S8.549
V. Wong
Background: Millennials represent a growing segment of the population that requires aesthetic treatments. Commonly, these individuals seek to undergo minimally invasive procedures to achieve ‘prejuvenation’ in order to delay the signs of aging because these procedures offer good aesthetic outcomes without the downtime and cost associated with more invasive options. Objective: Agents used for resurfacing, skin tone correction, and biorevitalising have been shown individually to address skin quality, melanogenesis, and rejuvenation, respectively. In this case report, the aim was to evaluate the overall prejuvenation effects of the combination of these agents in millennial subjects. Case description: Two patients with hyperpigmentation were evaluated prior to and after the prescribed regimen. Apparent improvements in skin quality and tone were documented after treatment. Conclusion: The combination of agents for prejuvenation was found to improve the overall quality of the skin and objectively reduced hypermelanosis in both male and female subjects.
{"title":"Resurface, Retone and Reboost: A Multi-Modality Approach for Prejuvenation of Millennial Patients","authors":"V. Wong","doi":"10.35248/2155-9554.21.S8.549","DOIUrl":"https://doi.org/10.35248/2155-9554.21.S8.549","url":null,"abstract":"Background: Millennials represent a growing segment of the population that requires aesthetic treatments. Commonly, these individuals seek to undergo minimally invasive procedures to achieve ‘prejuvenation’ in order to delay the signs of aging because these procedures offer good aesthetic outcomes without the downtime and cost associated with more invasive options. Objective: Agents used for resurfacing, skin tone correction, and biorevitalising have been shown individually to address skin quality, melanogenesis, and rejuvenation, respectively. In this case report, the aim was to evaluate the overall prejuvenation effects of the combination of these agents in millennial subjects. Case description: Two patients with hyperpigmentation were evaluated prior to and after the prescribed regimen. Apparent improvements in skin quality and tone were documented after treatment. Conclusion: The combination of agents for prejuvenation was found to improve the overall quality of the skin and objectively reduced hypermelanosis in both male and female subjects.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"18 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86472042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.S8.547
S. Hussein, M. Sorour, A. Hossain, Shaimaa Ahmed Abd el Azim, A. Soliman, Hany Shehata, Noha S Hanafy
Vitiligo is an idiopathic disorder of skin and hair characterized by melanin loss. Nonetheless thyroid disorder is a major cause of this pathology, other factors participate in its expression. Hormones such as, testosterone and estrogen have been suspected as drivers of this disorder. The present study aimed to determine the levels of testosterone and estrogen in serum of vitiligo patients. The study included 30 patients with vitiligo lesions (18 males and 12 females; ages ranged from 28–40 years and 30 healthy volunteers as control group (17 males and 13 females; ages ranged from 25-40years). All patients of vitiligo were recruited from Medical research center of excellence of National Research Centre, Egypt, during a period of 4 months (August 2020 to November 2020). Average period of the disorder in vitiligo group was 5.0 years. Vitiligo diagnosis is done clinically and confirmed using Wood’s lamp. Blood samples were taken from both the patient and control groups, testosterone and estrogen were assessed. Results: The present study declared a significant increase in the level of testosterone in males of VP compared to control, while significant increase in estrogen level in females of VP related to their corresponding control. Conclusion: some hormonal indicators have a role in pathogenesis of vitiligo where their disturbance leads to melanocyte destruction and/or depigmentation.
{"title":"Sex Hormones Assessment in Vitiligo Patient's Serum","authors":"S. Hussein, M. Sorour, A. Hossain, Shaimaa Ahmed Abd el Azim, A. Soliman, Hany Shehata, Noha S Hanafy","doi":"10.35248/2155-9554.21.S8.547","DOIUrl":"https://doi.org/10.35248/2155-9554.21.S8.547","url":null,"abstract":"Vitiligo is an idiopathic disorder of skin and hair characterized by melanin loss. Nonetheless thyroid disorder is a major cause of this pathology, other factors participate in its expression. Hormones such as, testosterone and estrogen have been suspected as drivers of this disorder. The present study aimed to determine the levels of testosterone and estrogen in serum of vitiligo patients. The study included 30 patients with vitiligo lesions (18 males and 12 females; ages ranged from 28–40 years and 30 healthy volunteers as control group (17 males and 13 females; ages ranged from 25-40years). All patients of vitiligo were recruited from Medical research center of excellence of National Research Centre, Egypt, during a period of 4 months (August 2020 to November 2020). Average period of the disorder in vitiligo group was 5.0 years. Vitiligo diagnosis is done clinically and confirmed using Wood’s lamp. Blood samples were taken from both the patient and control groups, testosterone and estrogen were assessed. Results: The present study declared a significant increase in the level of testosterone in males of VP compared to control, while significant increase in estrogen level in females of VP related to their corresponding control. Conclusion: some hormonal indicators have a role in pathogenesis of vitiligo where their disturbance leads to melanocyte destruction and/or depigmentation.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"66 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83408372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.S9.E118
P. R. Cunha
{"title":"Hyperpigmentation is a Common Skin Condition","authors":"P. R. Cunha","doi":"10.35248/2155-9554.21.S9.E118","DOIUrl":"https://doi.org/10.35248/2155-9554.21.S9.E118","url":null,"abstract":"","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"34 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83850183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: SJS and TEN are severe life threatening muco-cutaneous reactions characterised by extensive epidermal sloughing with mucosal erosions. Objective: The main objective of this study was to observe the effectiveness of cyclosporine in reducing the mortality and healing time of lesions in patients of SJS and TEN. Methods: The present work was designed as a retrospective tertiary urban hospital based, observational study during the period from March 2019 to Feb 2020. Detailed history, physical examination including cutaneous examination was done at the time of admission and the assessment of lesions using SCORTEN scoring was done at baseline, on day 3 and on tenth day of cyclosporine. All the routine investigations were done in each case. As per hospital records, oral cyclosporine in the dose of 5 mg/kg body weight per day was given to each patient for ten days.
{"title":"The Role of Oral Cyclosporine in the Management of Steven Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Multicentric Observational Study","authors":"Rajnish Kumar, Rashmi Singh, U. Udayan","doi":"10.46889/jdr.2021.2303","DOIUrl":"https://doi.org/10.46889/jdr.2021.2303","url":null,"abstract":"Background: SJS and TEN are severe life threatening muco-cutaneous reactions characterised by extensive epidermal sloughing with mucosal erosions. Objective: The main objective of this study was to observe the effectiveness of cyclosporine in reducing the mortality and healing time of lesions in patients of SJS and TEN. Methods: The present work was designed as a retrospective tertiary urban hospital based, observational study during the period from March 2019 to Feb 2020. Detailed history, physical examination including cutaneous examination was done at the time of admission and the assessment of lesions using SCORTEN scoring was done at baseline, on day 3 and on tenth day of cyclosporine. All the routine investigations were done in each case. As per hospital records, oral cyclosporine in the dose of 5 mg/kg body weight per day was given to each patient for ten days.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87808822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2155-9554.21.12.566
Laura Alessi, M. Aloisi, V. Amadu, A. Arena, Y. Balice, S. Bano, S. Barruscotti, A. Bartolotta, Silvia Bondino, A. Corsini, D. Nunno, S. Farina, P. Nappa, L. Pisano, Fabrizio Presta, N. Rivetti, E. Saccani, M. Tomassini, S. Torti, F. Vaira, G. Zanframundo, M. Puviani, K. Eisendle, M. Milani
Background and trial objectives: A new propylene glycol (PG)-free 5% minoxidil (PG-Free-Mnx) lotion has been recently commercialized. Clinical efficacy and local tolerability have been, so far, documented in a limited number of patients. The aim of this study was to evaluate the clinical efficacy, cosmetic acceptability, and local tolerability of 6-month application of this new PG-Free Mnx lotion in a real-life situation. Materials and methods: The NOMINAL (NO-PG MINoxidil reAL life study) trial was performed in 22 out-patients Italian dermatology clinics. A total of 196 subjects of both sexes with a diagnosis of AGA/FAGA were enrolled in the trial, after their written informed consent. PG-Free-Mnx lotion was applied 1 ml twice daily for 6 months. Clinical efficacy was evaluated in an open fashion in all the enrolled subjects with a 5-grade scale score (from-2: severe worsening, to +2: very good improvement in comparison with baseline condition). In a subgroup of subjects (n=60) an assessor-blinded clinical efficacy evaluation has been also performed using high definition standardized and coded scalp global pictures at baseline, and after 6 months by an assessor unaware of the temporal sequence using a 3-grade score (from 0: no improvement to 3: very high improvement). Cosmetic acceptability evaluation was assessed using a 7-item questionnaire using a 10-point scale score, with score 1meaning not at all and score 10 meaning the worst possible condition. Cosmetic acceptability and clinical efficacy were evaluated after 12 and 24 weeks of treatment. Global tolerability, assessed at week 24, was evaluated with a 4-grade scale score (from -1: very low tolerability to +2: very good tolerability). Results: All but seven (3.6%) subjects concluded the study. Clinical efficacy scores (open evaluation) were 0.8 ± 0.7 and 1.0 ± 0.7 at week 12 and 24, respectively. Good or very good clinical response (score +1 or +2) at week 12 and week 24 was observed in 64% and 74% respectively of the subjects with a similar response in women (75%) and men (73%). Baseline severity of AGA/FAGA was inversely correlated with the clinical response with a better outcome in subjects with AGA type II in comparison with subjects with types III/ IV AGA. The clinical efficacy was confirmed by the assessor-blinded evaluation of the subgroup of 60 subjects’ pictures at baseline (clinical score at baseline: 0.2 ± 0.4 vs. 1.8 ± 0.7 after 6 months; p=0.0001; absolute mean difference: 1.6; 95% CI: 1.1 to 2.0). Cosmetic acceptability score mean values were always 7) burning, itching or redness sensations. Conclusion: This new PG-free lotion shows, in real-life conditions, a very good cosmetic acceptability and tolerability profile. Clinical efficacy, evaluated both in open and assessor-blinded fashions, was also documented, and it was in line with the available data of traditional Mnx formulations with propylene glycol.
{"title":"Clinical Efficacy, Cosmetic Acceptability, and Local Tolerability of a New Formulation of Topical 5% Minoxidil without Propylene glycol: A 6-month, Multicentre, Real-life, Prospective, Assessor-Blinded Study in 196 Subjects with Hair Loss. The andldquo;NOMINALandrdquo; Trial","authors":"Laura Alessi, M. Aloisi, V. Amadu, A. Arena, Y. Balice, S. Bano, S. Barruscotti, A. Bartolotta, Silvia Bondino, A. Corsini, D. Nunno, S. Farina, P. Nappa, L. Pisano, Fabrizio Presta, N. Rivetti, E. Saccani, M. Tomassini, S. Torti, F. Vaira, G. Zanframundo, M. Puviani, K. Eisendle, M. Milani","doi":"10.35248/2155-9554.21.12.566","DOIUrl":"https://doi.org/10.35248/2155-9554.21.12.566","url":null,"abstract":"Background and trial objectives: A new propylene glycol (PG)-free 5% minoxidil (PG-Free-Mnx) lotion has been recently commercialized. Clinical efficacy and local tolerability have been, so far, documented in a limited number of patients. The aim of this study was to evaluate the clinical efficacy, cosmetic acceptability, and local tolerability of 6-month application of this new PG-Free Mnx lotion in a real-life situation. Materials and methods: The NOMINAL (NO-PG MINoxidil reAL life study) trial was performed in 22 out-patients Italian dermatology clinics. A total of 196 subjects of both sexes with a diagnosis of AGA/FAGA were enrolled in the trial, after their written informed consent. PG-Free-Mnx lotion was applied 1 ml twice daily for 6 months. Clinical efficacy was evaluated in an open fashion in all the enrolled subjects with a 5-grade scale score (from-2: severe worsening, to +2: very good improvement in comparison with baseline condition). In a subgroup of subjects (n=60) an assessor-blinded clinical efficacy evaluation has been also performed using high definition standardized and coded scalp global pictures at baseline, and after 6 months by an assessor unaware of the temporal sequence using a 3-grade score (from 0: no improvement to 3: very high improvement). Cosmetic acceptability evaluation was assessed using a 7-item questionnaire using a 10-point scale score, with score 1meaning not at all and score 10 meaning the worst possible condition. Cosmetic acceptability and clinical efficacy were evaluated after 12 and 24 weeks of treatment. Global tolerability, assessed at week 24, was evaluated with a 4-grade scale score (from -1: very low tolerability to +2: very good tolerability). Results: All but seven (3.6%) subjects concluded the study. Clinical efficacy scores (open evaluation) were 0.8 ± 0.7 and 1.0 ± 0.7 at week 12 and 24, respectively. Good or very good clinical response (score +1 or +2) at week 12 and week 24 was observed in 64% and 74% respectively of the subjects with a similar response in women (75%) and men (73%). Baseline severity of AGA/FAGA was inversely correlated with the clinical response with a better outcome in subjects with AGA type II in comparison with subjects with types III/ IV AGA. The clinical efficacy was confirmed by the assessor-blinded evaluation of the subgroup of 60 subjects’ pictures at baseline (clinical score at baseline: 0.2 ± 0.4 vs. 1.8 ± 0.7 after 6 months; p=0.0001; absolute mean difference: 1.6; 95% CI: 1.1 to 2.0). Cosmetic acceptability score mean values were always 7) burning, itching or redness sensations. Conclusion: This new PG-free lotion shows, in real-life conditions, a very good cosmetic acceptability and tolerability profile. Clinical efficacy, evaluated both in open and assessor-blinded fashions, was also documented, and it was in line with the available data of traditional Mnx formulations with propylene glycol.","PeriodicalId":15448,"journal":{"name":"Journal of clinical & experimental dermatology research","volume":"20 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84913055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：